US2010287626A1PendingUtilityA1

Method of screening ptp zeta activity promoter or inhibitor

Assignee: JAPAN SCIENCE & TECH AGENCYPriority: Jul 24, 2000Filed: Apr 8, 2009Published: Nov 11, 2010
Est. expiryJul 24, 2020(expired)· nominal 20-yr term from priority
A61P 43/00A61P 25/00G01N 33/68G01N 2333/205A01K 2267/0368G01N 33/5088C12N 9/16C12N 15/8509A01K 2217/075A61P 1/04A01K 2267/0393A01K 2227/105A01K 2267/03C12Q 1/42A01K 67/0276A01K 2267/0356
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An object of the present invention is to provide a remedy for dysfunction of central monoamine pathway, a method for screening a PTPζ inhibitor or activator, which is useful as a remedy for gastric ulcer caused by Helicobacter pylori or pleiotrophin which is a heparin-binding secretory protein, and a non-human model animal being hyposensitive to a stimulant drug, VacA which is a toxin of Helicobacter pylori , or pleiotrophin by utilizing the physiological function of PTPζ. After administering a subject material to PTPζ knockout mice and wild-type mice, PTPζ activity in the PTPζ knockout mice and the wild-type mice is compared and evaluated to screen a PTPζ inhibitor or activator. Examples of the comparison and the evaluation of the PTPζ activity include the comparison and the evaluation of the function of central monoamine pathway such as changes in the level of central monoamine metabolism, sensitivity to a stimulant drug, the presence of dysfunction of mesolimbic dopamine pathway, level of acclimation to new circumstances, or stress-responsiveness, and the comparison and the evaluation of the level of binding to VacA, a toxin of Helicobacter pylori , or pleiotrophin.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A method for using rodent as a model rodent being hyposensitive to a stimulant drug (an addictive drug), wherein the rodent whose function of gene DNA that encodes proteoglycan-type receptor-type protein tyrosine phosphatase (PTPζ) is homozygously deficient on its chromosome. 
     
     
         23 . The method according to  claim 22 , wherein the rodent is hyposensitive to a methamphetamine. 
     
     
         24 . The method according to  claim 22 , wherein the rodent whose function of gene DNA that encodes PTPζ is homozygously deficient on its chromosome is purified by being backcrossed for 4 or more generations. 
     
     
         25 . The method according to  claim 22 , wherein the rodent is a mouse. 
     
     
         26 . A method for using rodent as a model rodent being hyposensitive to VacA, a toxin of  Helicobacter pylori , wherein the rodent whose function of gene DNA that encodes proteoglycan-type receptor-type protein tyrosine phosphatase (PTPζ) is homozygously deficient on its chromosome. 
     
     
         27 . A method for using rodent as a model rodent being hyposensitive to pleiotrophin, a heparin-binding secretory protein, wherein the rodent whose function of gene DNA that encodes proteoglycan-type receptor-type protein tyrosine phosphatase (PTPζ) is homozygously deficient on its chromosome. 
     
     
         28 . The method according to  claim 26 , wherein the rodent whose function of gene DNA that encodes PTPζ is homozygously deficient on its chromosome is purified by being backcrossed for 4 or more generations. 
     
     
         29 . The method according to  claim 26 , wherein the rodent is a mouse.

Join the waitlist — get patent alerts

Track US2010287626A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.